Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies
(2005) In Journal of Medical Genetics 42(7). p.602-603- Abstract
- A recent report estimated the breast cancer risks in carriers of the three Ashkenazi founder mutations to be higher than previously published estimates derived from population based studies. In an attempt to confirm this, the breast and ovarian cancer risks associated with the three Ashkenazi founder mutations were estimated using families included in a previous meta-analysis of populatrion based studies. The estimated breast cancer risks for each of the founder BRCA1 and BRCA2 mutations were similar to the corresponding estimates based on all BRCA1 or BRCA2 mutations in the meta-analysis. These estimates appear to be consistent with the observed prevalence of the mutations in the Ashkenazi Jewish population.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/233800
- author
- organization
- publishing date
- 2005
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Journal of Medical Genetics
- volume
- 42
- issue
- 7
- pages
- 602 - 603
- publisher
- BMJ Publishing Group
- external identifiers
-
- wos:000230235800012
- pmid:15994883
- scopus:22244467729
- ISSN
- 0022-2593
- DOI
- 10.1136/jmg.2004.024133
- language
- English
- LU publication?
- yes
- id
- b91dac3e-719d-4ff7-9615-35c011debc41 (old id 233800)
- date added to LUP
- 2016-04-01 16:34:37
- date last changed
- 2022-02-20 07:00:14
@article{b91dac3e-719d-4ff7-9615-35c011debc41, abstract = {{A recent report estimated the breast cancer risks in carriers of the three Ashkenazi founder mutations to be higher than previously published estimates derived from population based studies. In an attempt to confirm this, the breast and ovarian cancer risks associated with the three Ashkenazi founder mutations were estimated using families included in a previous meta-analysis of populatrion based studies. The estimated breast cancer risks for each of the founder BRCA1 and BRCA2 mutations were similar to the corresponding estimates based on all BRCA1 or BRCA2 mutations in the meta-analysis. These estimates appear to be consistent with the observed prevalence of the mutations in the Ashkenazi Jewish population.}}, author = {{Antoniou, A C and Pharoah, P D P and Narod, S and Risch, H A and Eyfjord, J E and Hopper, J L and Olsson, Håkan and Johannsson, O and Borg, Åke and Pasini, B and Radice, P and Manoukian, S and Eccles, D M and Tang, N and Olah, E and Anton-Culver, H and Warner, E and Lubinski, J and Gronwald, J and Gorski, B and Tulinius, H and Thorlacius, S and Eerola, H and Nevanlinna, H and Syrjakoski, K and Kallioniemi, O P and Thompson, D and Evans, C and Peto, J and Lalloo, F and Evans, D G and Easton, D F}}, issn = {{0022-2593}}, language = {{eng}}, number = {{7}}, pages = {{602--603}}, publisher = {{BMJ Publishing Group}}, series = {{Journal of Medical Genetics}}, title = {{Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies}}, url = {{http://dx.doi.org/10.1136/jmg.2004.024133}}, doi = {{10.1136/jmg.2004.024133}}, volume = {{42}}, year = {{2005}}, }